AustralieFrV1, Main, Exploration, bibRecord, 008690

First-line bevacizumab combined with reduced dose interferon-α2a is active in patients with metastatic renal cell carcinoma

Identifieur interne : 008690 ( Main/Exploration ); précédent : 008689; suivant : 008691

First-line bevacizumab combined with reduced dose interferon-α2a is active in patients with metastatic renal cell carcinoma

Auteurs : B. Melichar [République tchèque] ; P. Koralewski [Pologne] ; A. Ravaud [France] ; A. Pluzanska [Pologne] ; S. Bracarda [Italie] ; C. Szczylik [Pologne] ; C. Chevreau [France] ; M. Filipek [Pologne] ; R. Delva ; E. Sevin ; S. Négrier [France] ; J. Mckendrick [Australie] ; A. Santoro [Italie] ; P. Pisa [Suisse] ; B. Escudier [France]

Source :

Annals of Oncology [ 0923-7534 ] ; 2008-04-11.

RBID : ISTEX:33B15B858FCC083B59F989364F684650EB57CAEF

Descripteurs français

Pascal (Inist)
- Antiangiogénique, Anticancéreux, Association médicamenteuse, Bévacizumab, Cancer rein, Carcinome, Cytokine, Dose faible, Facteur croissance endothélium vasculaire, Homme, Hypernéphrome, Interféron, Métastase, Stade avancé, Traitement de première intention.
Wicri :
- topic : Homme.

English descriptors

KwdEn :
- Advanced stage, Antiangiogenic agent, Antineoplastic agent, Bevacizumab, Carcinoma, Cytokine, Drug combination, First line treatment, Grawitz tumor, Human, Interferon, Kidney cancer, Low dose, Metastasis, Vascular endothelium growth factor.

Abstract

Background: In patients with untreated metastatic renal cell carcinoma (mRCC), progression-free survival (PFS) was longer with bevacizumab + interferon (IFN)-α than IFN + placebo (AVOREN trial). In this hypothesis-generating study, subgroup analysis was carried out to determine the effect of IFN dose reduction. Patients and methods: A total of 649 patients received IFN 9 MIU s.c. three times weekly plus bevacizumab 10 mg/kg or placebo every 2 weeks until disease progression. The IFN dose was reduced to 6 or 3 MIU with the development of IFN-attributed toxicity. Differences between treatment arms in PFS, response rate and tolerability were analysed in the reduced-dose group. Results: IFN dose was reduced in 131 patients in the bevacizumab + IFN arm and 97 patients in the IFN + placebo arm during the trial. PFS rates in the bevacizumab + reduced-dose IFN group were comparable with the total population (Kaplan–Meier estimates of event-free rate at 1 year: 0.524 versus 0.427). Bevacizumab + reduced-dose IFN was well tolerated, with substantial decreases in the rate of adverse events following dose reduction. Conclusion: This retrospective subgroup analysis suggests that the dose of IFN can be reduced to manage side-effects while maintaining efficacy in patients with mRCC receiving bevacizumab + IFN.

Url:

https://api.istex.fr/document/33B15B858FCC083B59F989364F684650EB57CAEF/fulltext/pdf

DOI: 10.1093/annonc/mdn161

Affiliations:

Le document en format XML

<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title>First-line bevacizumab combined with reduced dose interferon-α2a is active in patients with metastatic renal cell carcinoma</title>
<author><name sortKey="Melichar, B" sort="Melichar, B" uniqKey="Melichar B" first="B." last="Melichar">B. Melichar</name>
</author>
<author><name sortKey="Koralewski, P" sort="Koralewski, P" uniqKey="Koralewski P" first="P." last="Koralewski">P. Koralewski</name>
</author>
<author><name sortKey="Ravaud, A" sort="Ravaud, A" uniqKey="Ravaud A" first="A." last="Ravaud">A. Ravaud</name>
</author>
<author><name sortKey="Pluzanska, A" sort="Pluzanska, A" uniqKey="Pluzanska A" first="A." last="Pluzanska">A. Pluzanska</name>
</author>
<author><name sortKey="Bracarda, S" sort="Bracarda, S" uniqKey="Bracarda S" first="S." last="Bracarda">S. Bracarda</name>
</author>
<author><name sortKey="Szczylik, C" sort="Szczylik, C" uniqKey="Szczylik C" first="C." last="Szczylik">C. Szczylik</name>
</author>
<author><name sortKey="Chevreau, C" sort="Chevreau, C" uniqKey="Chevreau C" first="C." last="Chevreau">C. Chevreau</name>
</author>
<author><name sortKey="Filipek, M" sort="Filipek, M" uniqKey="Filipek M" first="M." last="Filipek">M. Filipek</name>
</author>
<author><name sortKey="Delva, R" sort="Delva, R" uniqKey="Delva R" first="R." last="Delva">R. Delva</name>
</author>
<author><name sortKey="Sevin, E" sort="Sevin, E" uniqKey="Sevin E" first="E." last="Sevin">E. Sevin</name>
</author>
<author><name sortKey="Negrier, S" sort="Negrier, S" uniqKey="Negrier S" first="S." last="Négrier">S. Négrier</name>
</author>
<author><name sortKey="Mckendrick, J" sort="Mckendrick, J" uniqKey="Mckendrick J" first="J." last="Mckendrick">J. Mckendrick</name>
</author>
<author><name sortKey="Santoro, A" sort="Santoro, A" uniqKey="Santoro A" first="A." last="Santoro">A. Santoro</name>
</author>
<author><name sortKey="Pisa, P" sort="Pisa, P" uniqKey="Pisa P" first="P." last="Pisa">P. Pisa</name>
</author>
<author><name sortKey="Escudier, B" sort="Escudier, B" uniqKey="Escudier B" first="B." last="Escudier">B. Escudier</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:33B15B858FCC083B59F989364F684650EB57CAEF</idno>
<date when="2008" year="2008">2008</date>
<idno type="doi">10.1093/annonc/mdn161</idno>
<idno type="url">https://api.istex.fr/document/33B15B858FCC083B59F989364F684650EB57CAEF/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">003052</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">003052</idno>
<idno type="wicri:Area/Istex/Curation">003052</idno>
<idno type="wicri:Area/Istex/Checkpoint">001050</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">001050</idno>
<idno type="wicri:doubleKey">0923-7534:2008:Melichar B:first:line:bevacizumab</idno>
<idno type="wicri:Area/Main/Merge">008F51</idno>
<idno type="wicri:source">INIST</idno>
<idno type="RBID">Pascal:08-0407697</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">003358</idno>
<idno type="wicri:Area/PascalFrancis/Curation">002C94</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">003228</idno>
<idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">003228</idno>
<idno type="wicri:doubleKey">0923-7534:2008:Melichar B:first:line:bevacizumab</idno>
<idno type="wicri:Area/Main/Merge">009642</idno>
<idno type="wicri:Area/Main/Curation">008690</idno>
<idno type="wicri:Area/Main/Exploration">008690</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a">First-line bevacizumab combined with reduced dose interferon-2a is active in patients with metastatic renal cell carcinoma</title>
<author><name sortKey="Melichar, B" sort="Melichar, B" uniqKey="Melichar B" first="B." last="Melichar">B. Melichar</name>
<affiliation wicri:level="1"><country xml:lang="fr">République tchèque</country>
<wicri:regionArea>Charles University Medical School and Teaching Hospital, Hradec Králové</wicri:regionArea>
<wicri:noRegion>Hradec Králové</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><country wicri:rule="url">République tchèque</country>
</affiliation>
<affiliation><wicri:noCountry code="syntax">???</wicri:noCountry>
</affiliation>
<affiliation wicri:level="1"><country wicri:rule="url">République tchèque</country>
</affiliation>
</author>
<author><name sortKey="Koralewski, P" sort="Koralewski, P" uniqKey="Koralewski P" first="P." last="Koralewski">P. Koralewski</name>
<affiliation wicri:level="1"><country xml:lang="fr">Pologne</country>
<wicri:regionArea>Szpital im. Rydygiera, Krakow</wicri:regionArea>
<wicri:noRegion>Krakow</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Ravaud, A" sort="Ravaud, A" uniqKey="Ravaud A" first="A." last="Ravaud">A. Ravaud</name>
<affiliation wicri:level="3"><country xml:lang="fr">France</country>
<wicri:regionArea>Department of Medical Oncology and Radiotherapy, Hôpital Saint André, CHU Bordeaux, Bordeaux</wicri:regionArea>
<placeName><region type="region">Nouvelle-Aquitaine</region>
<region type="old region">Aquitaine</region>
<settlement type="city">Bordeaux</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Pluzanska, A" sort="Pluzanska, A" uniqKey="Pluzanska A" first="A." last="Pluzanska">A. Pluzanska</name>
<affiliation wicri:level="1"><country xml:lang="fr">Pologne</country>
<wicri:regionArea>Klinika Chemioterapii AM, Lodz</wicri:regionArea>
<wicri:noRegion>Lodz</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Bracarda, S" sort="Bracarda, S" uniqKey="Bracarda S" first="S." last="Bracarda">S. Bracarda</name>
<affiliation wicri:level="1"><country xml:lang="fr">Italie</country>
<wicri:regionArea>Department of Medical Oncology, Azienda Ospedaliera, Perugia</wicri:regionArea>
<wicri:noRegion>Perugia</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Szczylik, C" sort="Szczylik, C" uniqKey="Szczylik C" first="C." last="Szczylik">C. Szczylik</name>
<affiliation wicri:level="1"><country xml:lang="fr">Pologne</country>
<wicri:regionArea>Oncology Clinic, Wojskowy Instytut Medyczny, Warsaw</wicri:regionArea>
<wicri:noRegion>Warsaw</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Chevreau, C" sort="Chevreau, C" uniqKey="Chevreau C" first="C." last="Chevreau">C. Chevreau</name>
<affiliation wicri:level="1"><country xml:lang="fr">France</country>
<wicri:regionArea>Department of Medical Oncology, Institut Claudius-Regaud, Toulouse Cedex</wicri:regionArea>
<wicri:noRegion>Toulouse Cedex</wicri:noRegion>
<wicri:noRegion>Toulouse Cedex</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Filipek, M" sort="Filipek, M" uniqKey="Filipek M" first="M." last="Filipek">M. Filipek</name>
<affiliation wicri:level="1"><country xml:lang="fr">Pologne</country>
<wicri:regionArea>Szpital Wojewodzki im. Sw. Lukasz, Tarnow</wicri:regionArea>
<wicri:noRegion>Tarnow</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Delva, R" sort="Delva, R" uniqKey="Delva R" first="R." last="Delva">R. Delva</name>
<affiliation><wicri:noCountry code="subField">Angers</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Sevin, E" sort="Sevin, E" uniqKey="Sevin E" first="E." last="Sevin">E. Sevin</name>
<affiliation><wicri:noCountry code="subField">Caen</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Negrier, S" sort="Negrier, S" uniqKey="Negrier S" first="S." last="Négrier">S. Négrier</name>
<affiliation wicri:level="3"><country xml:lang="fr">France</country>
<wicri:regionArea>Department of Medical Oncology, Centre Léon Bérard, Lyon</wicri:regionArea>
<placeName><region type="region">Auvergne-Rhône-Alpes</region>
<region type="old region">Rhône-Alpes</region>
<settlement type="city">Lyon</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Mckendrick, J" sort="Mckendrick, J" uniqKey="Mckendrick J" first="J." last="Mckendrick">J. Mckendrick</name>
<affiliation wicri:level="1"><country xml:lang="fr">Australie</country>
<wicri:regionArea>Department of Medical Oncology, Box Hill Hospital, Box Hill</wicri:regionArea>
<wicri:noRegion>Box Hill</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Santoro, A" sort="Santoro, A" uniqKey="Santoro A" first="A." last="Santoro">A. Santoro</name>
<affiliation wicri:level="1"><country xml:lang="fr">Italie</country>
<wicri:regionArea>Department of Oncology and Hematology, Istituto Clinico Humanitas, Rozzano</wicri:regionArea>
<wicri:noRegion>Rozzano</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Pisa, P" sort="Pisa, P" uniqKey="Pisa P" first="P." last="Pisa">P. Pisa</name>
<affiliation wicri:level="1"><country xml:lang="fr">Suisse</country>
<wicri:regionArea>F. Hoffmann-La Roche Ltd, Basel</wicri:regionArea>
<wicri:noRegion>Basel</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Escudier, B" sort="Escudier, B" uniqKey="Escudier B" first="B." last="Escudier">B. Escudier</name>
<affiliation wicri:level="1"><country xml:lang="fr">France</country>
<wicri:regionArea>Department of Medicine, Institut Gustave Roussy, Villejuif</wicri:regionArea>
<wicri:noRegion>Villejuif</wicri:noRegion>
<wicri:noRegion>Villejuif</wicri:noRegion>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Annals of Oncology</title>
<idno type="ISSN">0923-7534</idno>
<idno type="eISSN">1569-8041</idno>
<imprint><publisher>Oxford University Press</publisher>
<date type="published" when="2008-04-11">2008-04-11</date>
<biblScope unit="volume">19</biblScope>
<biblScope unit="issue">8</biblScope>
<biblScope unit="page" from="1470">1470</biblScope>
<biblScope unit="page" to="1476">1476</biblScope>
</imprint>
<idno type="ISSN">0923-7534</idno>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0923-7534</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Advanced stage</term>
<term>Antiangiogenic agent</term>
<term>Antineoplastic agent</term>
<term>Bevacizumab</term>
<term>Carcinoma</term>
<term>Cytokine</term>
<term>Drug combination</term>
<term>First line treatment</term>
<term>Grawitz tumor</term>
<term>Human</term>
<term>Interferon</term>
<term>Kidney cancer</term>
<term>Low dose</term>
<term>Metastasis</term>
<term>Vascular endothelium growth factor</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Antiangiogénique</term>
<term>Anticancéreux</term>
<term>Association médicamenteuse</term>
<term>Bévacizumab</term>
<term>Cancer rein</term>
<term>Carcinome</term>
<term>Cytokine</term>
<term>Dose faible</term>
<term>Facteur croissance endothélium vasculaire</term>
<term>Homme</term>
<term>Hypernéphrome</term>
<term>Interféron</term>
<term>Métastase</term>
<term>Stade avancé</term>
<term>Traitement de première intention</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract">Background: In patients with untreated metastatic renal cell carcinoma (mRCC), progression-free survival (PFS) was longer with bevacizumab + interferon (IFN)-α than IFN + placebo (AVOREN trial). In this hypothesis-generating study, subgroup analysis was carried out to determine the effect of IFN dose reduction. Patients and methods: A total of 649 patients received IFN 9 MIU s.c. three times weekly plus bevacizumab 10 mg/kg or placebo every 2 weeks until disease progression. The IFN dose was reduced to 6 or 3 MIU with the development of IFN-attributed toxicity. Differences between treatment arms in PFS, response rate and tolerability were analysed in the reduced-dose group. Results: IFN dose was reduced in 131 patients in the bevacizumab + IFN arm and 97 patients in the IFN + placebo arm during the trial. PFS rates in the bevacizumab + reduced-dose IFN group were comparable with the total population (Kaplan–Meier estimates of event-free rate at 1 year: 0.524 versus 0.427). Bevacizumab + reduced-dose IFN was well tolerated, with substantial decreases in the rate of adverse events following dose reduction. Conclusion: This retrospective subgroup analysis suggests that the dose of IFN can be reduced to manage side-effects while maintaining efficacy in patients with mRCC receiving bevacizumab + IFN.</div>
</front>
</TEI>
<affiliations><list><country><li>Australie</li>
<li>France</li>
<li>Italie</li>
<li>Pologne</li>
<li>République tchèque</li>
<li>Suisse</li>
</country>
<region><li>Aquitaine</li>
<li>Auvergne-Rhône-Alpes</li>
<li>Nouvelle-Aquitaine</li>
<li>Rhône-Alpes</li>
</region>
<settlement><li>Bordeaux</li>
<li>Lyon</li>
</settlement>
</list>
<tree><noCountry><name sortKey="Delva, R" sort="Delva, R" uniqKey="Delva R" first="R." last="Delva">R. Delva</name>
<name sortKey="Sevin, E" sort="Sevin, E" uniqKey="Sevin E" first="E." last="Sevin">E. Sevin</name>
</noCountry>
<country name="République tchèque"><noRegion><name sortKey="Melichar, B" sort="Melichar, B" uniqKey="Melichar B" first="B." last="Melichar">B. Melichar</name>
</noRegion>
<name sortKey="Melichar, B" sort="Melichar, B" uniqKey="Melichar B" first="B." last="Melichar">B. Melichar</name>
<name sortKey="Melichar, B" sort="Melichar, B" uniqKey="Melichar B" first="B." last="Melichar">B. Melichar</name>
</country>
<country name="Pologne"><noRegion><name sortKey="Koralewski, P" sort="Koralewski, P" uniqKey="Koralewski P" first="P." last="Koralewski">P. Koralewski</name>
</noRegion>
<name sortKey="Filipek, M" sort="Filipek, M" uniqKey="Filipek M" first="M." last="Filipek">M. Filipek</name>
<name sortKey="Pluzanska, A" sort="Pluzanska, A" uniqKey="Pluzanska A" first="A." last="Pluzanska">A. Pluzanska</name>
<name sortKey="Szczylik, C" sort="Szczylik, C" uniqKey="Szczylik C" first="C." last="Szczylik">C. Szczylik</name>
</country>
<country name="France"><region name="Nouvelle-Aquitaine"><name sortKey="Ravaud, A" sort="Ravaud, A" uniqKey="Ravaud A" first="A." last="Ravaud">A. Ravaud</name>
</region>
<name sortKey="Chevreau, C" sort="Chevreau, C" uniqKey="Chevreau C" first="C." last="Chevreau">C. Chevreau</name>
<name sortKey="Escudier, B" sort="Escudier, B" uniqKey="Escudier B" first="B." last="Escudier">B. Escudier</name>
<name sortKey="Negrier, S" sort="Negrier, S" uniqKey="Negrier S" first="S." last="Négrier">S. Négrier</name>
</country>
<country name="Italie"><noRegion><name sortKey="Bracarda, S" sort="Bracarda, S" uniqKey="Bracarda S" first="S." last="Bracarda">S. Bracarda</name>
</noRegion>
<name sortKey="Santoro, A" sort="Santoro, A" uniqKey="Santoro A" first="A." last="Santoro">A. Santoro</name>
</country>
<country name="Australie"><noRegion><name sortKey="Mckendrick, J" sort="Mckendrick, J" uniqKey="Mckendrick J" first="J." last="Mckendrick">J. Mckendrick</name>
</noRegion>
</country>
<country name="Suisse"><noRegion><name sortKey="Pisa, P" sort="Pisa, P" uniqKey="Pisa P" first="P." last="Pisa">P. Pisa</name>
</noRegion>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 008690 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 008690 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Asie
   |area=    AustralieFrV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     ISTEX:33B15B858FCC083B59F989364F684650EB57CAEF
   |texte=   First-line bevacizumab combined with reduced dose interferon-α2a is active in patients with metastatic renal cell carcinoma
}}

This area was generated with Dilib version V0.6.33.
Data generation: Tue Dec 5 10:43:12 2017. Site generation: Tue Mar 5 14:07:20 2024

Serveur d'exploration sur les relations entre la France et l'Australie

First-line bevacizumab combined with reduced dose interferon-α2a is active in patients with metastatic renal cell carcinoma

First-line bevacizumab combined with reduced dose interferon-α2a is active in patients with metastatic renal cell carcinoma

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

	Serveur d'exploration sur les relations entre la France et l'Australie
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.